Cosmo Pharmaceuticals Announces Submission of Remimazolam NDA to FDA

Dublin– April 9, 2019– Cosmo Pharmaceuticals NV (SIX: COPN) today informed that the Remimazolam NDA has been submitted to FDA. Electronic acknowledgment of the submission shows April 5 as the official date of submission. Therefore...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news